EcoDrugPlus

Histone Deacetylase 5

Ensembl ID : ENSXMAG00000017412
Gene Symbol: HDAC5
3 Cross references
194 Possible Orthologues:

Histone Deacetylase 6

Ensembl ID : ENSXMAG00000013014
Gene Symbol: HDAC6
2 Cross references
180 Possible Orthologues:

Histone Deacetylase 7

Ensembl ID : ENSXMAG00000004559
Gene Symbol: HDAC7
3 Cross references
189 Possible Orthologues:

Histone Deacetylase 7-Like

Ensembl ID : ENSXMAG00000018719
Gene Symbol: LOC102216565
2 Cross references
195 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSXMAG00000014850
Gene Symbol: HDAC8
3 Cross references
205 Possible Orthologues:

Hydroxycarboxylic Acid Receptor 1

Ensembl ID : ENSXMAG00000020330
Gene Symbol: HCAR1
2 Cross references
233 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSXMAG00000000037
Gene Symbol: HCN4
3 Cross references
221 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSXMAG00000026550
Gene Symbol: HCN4
3 Cross references
212 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSXMAG00000010192
Gene Symbol: HCRTR2
3 Cross references
203 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Homolog

Ensembl ID : ENSXMAG00000028458
Gene Symbol: LOC102230859
3 Cross references
211 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSXMAG00000014460
Gene Symbol: IKBKB
3 Cross references
199 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSXMAG00000019354
Gene Symbol: IMPDH2
4 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).